Tumor-specific adenoviral gene therapy: transcriptional repression of gene expression by utilizing p53-signal transduction pathways
- 18 December 2003
- journal article
- research article
- Published by Springer Nature in Cancer Gene Therapy
- Vol. 11 (1) , 28-40
- https://doi.org/10.1038/sj.cgt.7700632
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- The IARC TP53 database: New online mutation analysis and recommendations to usersHuman Mutation, 2002
- Telomerase-specific suicide gene therapy vectors expressing bacterial nitroreductase sensitize human cancer cells to the pro-drug CB1954Oncogene, 2001
- Prostate-specific expression of Bax delivered by an adenoviral vector induces apoptosis in LNCaP prostate cancer cellsGene Therapy, 2001
- Use of Transcriptional Regulatory Sequences of Telomerase (hTER and hTERT) for Selective Killing of Cancer CellsMolecular Therapy, 2000
- The Hallmarks of CancerCell, 2000
- Analysis of the human carcinoembryonic antigen promoter core region in colorectal carcinoma-selective cytosine deaminase gene therapyCancer Gene Therapy, 1999
- p53, the Cellular Gatekeeper for Growth and DivisionCell, 1997
- Adenovirus E1A Proteins Inhibit Activation of Transcription by p53Molecular and Cellular Biology, 1996
- mdm-2 Inhibits the G1 Arrest and Apoptosis Functions of the p53 Tumor Suppressor ProteinMolecular and Cellular Biology, 1996
- Functional inactivation but not structural mutation of p53 causes liver cancerNature Genetics, 1995